Logo image of CLLS

CELLECTIS - ADR (CLLS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CLLS - US15117K1034 - ADR

4.41 USD
-0.07 (-1.56%)
Last: 1/9/2026, 4:30:00 PM
Fundamental Rating

2

Overall CLLS gets a fundamental rating of 2 out of 10. We evaluated CLLS against 530 industry peers in the Biotechnology industry. CLLS may be in some trouble as it scores bad on both profitability and health. CLLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLLS had negative earnings in the past year.
In the past year CLLS has reported a negative cash flow from operations.
In the past 5 years CLLS always reported negative net income.
In the past 5 years CLLS reported 4 times negative operating cash flow.
CLLS Yearly Net Income VS EBIT VS OCF VS FCFCLLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

The Return On Assets of CLLS (-28.30%) is better than 69.06% of its industry peers.
CLLS has a Return On Equity (-103.16%) which is in line with its industry peers.
Industry RankSector Rank
ROA -28.3%
ROE -103.16%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
CLLS Yearly ROA, ROE, ROICCLLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CLLS has a better Gross Margin (3.66%) than 72.08% of its industry peers.
CLLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLLS Yearly Profit, Operating, Gross MarginsCLLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

CLLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLLS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CLLS has more shares outstanding
CLLS has a better debt/assets ratio than last year.
CLLS Yearly Shares OutstandingCLLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLLS Yearly Total Debt VS Total AssetsCLLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -0.35, we must say that CLLS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.35, CLLS perfoms like the industry average, outperforming 59.06% of the companies in the same industry.
CLLS has a Debt/Equity ratio of 0.91. This is a neutral value indicating CLLS is somewhat dependend on debt financing.
CLLS has a Debt to Equity ratio of 0.91. This is in the lower half of the industry: CLLS underperforms 73.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Altman-Z -0.35
ROIC/WACCN/A
WACC6.75%
CLLS Yearly LT Debt VS Equity VS FCFCLLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

CLLS has a Current Ratio of 1.38. This is a normal value and indicates that CLLS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.38, CLLS is doing worse than 82.08% of the companies in the same industry.
CLLS has a Quick Ratio of 1.38. This is a normal value and indicates that CLLS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CLLS (1.38) is worse than 80.94% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.38
CLLS Yearly Current Assets VS Current LiabilitesCLLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

CLLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.80%, which is quite impressive.
Looking at the last year, CLLS shows a very strong growth in Revenue. The Revenue has grown by 154.92%.
CLLS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.44% yearly.
EPS 1Y (TTM)70.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.35%
Revenue 1Y (TTM)154.92%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%105.89%

3.2 Future

CLLS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -54.16% yearly.
The Revenue is expected to grow by 25.15% on average over the next years. This is a very strong growth
EPS Next Y-166.15%
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%
EPS Next 5YN/A
Revenue Next Year45.52%
Revenue Next 2Y32.52%
Revenue Next 3Y9.94%
Revenue Next 5Y25.15%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLLS Yearly Revenue VS EstimatesCLLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
CLLS Yearly EPS VS EstimatesCLLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLLS Price Earnings VS Forward Price EarningsCLLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLLS Per share dataCLLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A cheap valuation may be justified as CLLS's earnings are expected to decrease with -54.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%

More info and screens

0

5. Dividend

5.1 Amount

CLLS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CELLECTIS - ADR

NASDAQ:CLLS (1/9/2026, 4:30:00 PM)

4.41

-0.07 (-1.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07/amc
Earnings (Next)03-11 2026-03-11/amc
Inst Owners15.56%
Inst Owner Change0%
Ins Owners2.82%
Ins Owner ChangeN/A
Market Cap442.43M
Revenue(TTM)112.63M
Net Income(TTM)-100.18M
Analysts84.62
Price Target7.77 (76.19%)
Short Float %0.54%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.93%
Min EPS beat(2)4.37%
Max EPS beat(2)25.48%
EPS beat(4)4
Avg EPS beat(4)48.46%
Min EPS beat(4)4.37%
Max EPS beat(4)145.69%
EPS beat(8)7
Avg EPS beat(8)30.86%
EPS beat(12)9
Avg EPS beat(12)22.27%
EPS beat(16)12
Avg EPS beat(16)21.56%
Revenue beat(2)1
Avg Revenue beat(2)21.17%
Min Revenue beat(2)-20.05%
Max Revenue beat(2)62.39%
Revenue beat(4)3
Avg Revenue beat(4)64.94%
Min Revenue beat(4)-20.05%
Max Revenue beat(4)161.56%
Revenue beat(8)5
Avg Revenue beat(8)33.5%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.29%
PT rev (3m)5.56%
EPS NQ rev (1m)-1.47%
EPS NQ rev (3m)-1.47%
EPS NY rev (1m)0.4%
EPS NY rev (3m)13.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)50.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.73
P/FCF N/A
P/OCF N/A
P/B 4.56
P/tB 4.61
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.93
BVpS0.97
TBVpS0.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.3%
ROE -103.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.66%
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.04%
Cap/Sales 3.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.38
Quick Ratio 1.38
Altman-Z -0.35
F-Score3
WACC6.75%
ROIC/WACCN/A
Cap/Depr(3y)12.8%
Cap/Depr(5y)139.39%
Cap/Sales(3y)9.66%
Cap/Sales(5y)33.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.35%
EPS Next Y-166.15%
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%
EPS Next 5YN/A
Revenue 1Y (TTM)154.92%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%105.89%
Revenue Next Year45.52%
Revenue Next 2Y32.52%
Revenue Next 3Y9.94%
Revenue Next 5Y25.15%
EBIT growth 1Y46.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.42%
EBIT Next 3Y-33.24%
EBIT Next 5Y-29.24%
FCF growth 1Y51.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.32%
OCF growth 3YN/A
OCF growth 5YN/A

CELLECTIS - ADR / CLLS FAQ

What is the ChartMill fundamental rating of CELLECTIS - ADR (CLLS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CLLS.


Can you provide the valuation status for CELLECTIS - ADR?

ChartMill assigns a valuation rating of 0 / 10 to CELLECTIS - ADR (CLLS). This can be considered as Overvalued.


How profitable is CELLECTIS - ADR (CLLS) stock?

CELLECTIS - ADR (CLLS) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CELLECTIS - ADR?

The Earnings per Share (EPS) of CELLECTIS - ADR (CLLS) is expected to decline by -166.15% in the next year.